Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Zhongguo Yao Li Xue Bao ; 16(3): 217-22, 1995 May.
Artigo em Inglês | MEDLINE | ID: mdl-7660814

RESUMO

AIM: To explore the mechanisms by which angiotensin converting enzyme inhibitor (ACEI) prevents the development of left ventricular hypertrophy (LVH). METHODS: Captopril (Cap 100 mg.kg(-1).d(-1)) was given orally to male spontaneously hypertensive rats from intrauterine period to 16 wk of age. Experiments were performed at 40 wk of age. SBP, left ventricular weight to body weight ratio (LVW/BW) were assessed. The levels of c-myc and c-fos mRNA in the left ventricle were measured by Northern blot. RESULTS: Early-onset Cap therapy significantly decreased SBP. After discontinuance of treatment for 24 wk, SBP of SHRcap was still maintained at a lower level. LVW/BW in SHRcap was markedly reduced. The expression of myocardial c-myc mRNA was decreased by 72% in SHRcap compared with that in the untreated SHR, but the expression of myocardial c-fos mRNA was not different between the untreated SHR, SHRcap, and WKY rats. CONCLUSION: Early Cap treatment may permanently prevent the development of hypertension, inhibit LVH. Furthermore, the prevention of LVH is associated with a decrease in c-myc mRNA levels, and the development and regression of left ventricular hypertrophy may be irrelevant to c-fos expression.


Assuntos
Captopril/uso terapêutico , Hipertrofia Ventricular Esquerda/prevenção & controle , Proteínas Proto-Oncogênicas c-fos/metabolismo , Proteínas Proto-Oncogênicas c-myc/metabolismo , RNA Mensageiro/biossíntese , Animais , Feminino , Expressão Gênica , Hipertrofia Ventricular Esquerda/genética , Masculino , Miocárdio/metabolismo , Proteínas Proto-Oncogênicas c-fos/genética , Proteínas Proto-Oncogênicas c-myc/genética , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKY
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA